Aberdeen Group’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-36,339
| Closed | -$587K | – | 974 |
|
|
2023
Q3 | $587K | Sell |
36,339
-9,088
| -20% | -$147K | ﹤0.01% | 802 |
|
|
2023
Q2 | $1.89M | Buy |
45,427
+1,672
| +4% | +$69.4K | ﹤0.01% | 730 |
|
|
2023
Q1 | $2.63M | Buy |
43,755
+10,746
| +33% | +$646K | 0.01% | 694 |
|
|
2022
Q4 | $2.42M | Buy |
33,009
+1,290
| +4% | +$94.6K | 0.01% | 681 |
|
|
2022
Q3 | $2.41M | Buy |
31,719
+10,474
| +49% | +$796K | 0.01% | 676 |
|
|
2022
Q2 | $1.48M | Buy |
21,245
+2,325
| +12% | +$162K | ﹤0.01% | 745 |
|
|
2022
Q1 | $1.57M | Buy |
18,920
+3,595
| +23% | +$297K | ﹤0.01% | 765 |
|
|
2021
Q4 | $1.15M | Buy |
15,325
+859
| +6% | +$64.5K | ﹤0.01% | 854 |
|
|
2021
Q3 | $1.68M | Buy |
14,466
+3,035
| +27% | +$353K | ﹤0.01% | 814 |
|
|
2021
Q2 | $2.54M | Sell |
11,431
-2,286
| -17% | -$507K | 0.01% | 727 |
|
|
2021
Q1 | $1.81M | Buy |
13,717
+8,072
| +143% | +$1.07M | ﹤0.01% | 777 |
|
|
2020
Q4 | $978K | Buy |
5,645
+1,230
| +28% | +$213K | ﹤0.01% | 833 |
|
|
2020
Q3 | $492K | Buy |
+4,415
| New | +$492K | ﹤0.01% | 850 |
|